Ekso Bionics Holdings, Inc.
DB:23E2 Rapporto sulle azioni
Ekso Bionics Holdings Salute del bilancio
Salute finanziaria criteri di controllo 4/6 Ekso Bionics Holdings ha un patrimonio netto totale di $14.9M e un debito totale di $5.4M, che porta il suo rapporto debito/patrimonio netto a 36%. Le sue attività totali e le sue passività totali sono rispettivamente $29.2M e $14.3M.
Informazioni chiave
36.0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$8.29m Patrimonio netto US$14.87m Totale passività US$14.34m Totale attività US$29.21m
Aggiornamenti recenti sulla salute finanziaria
Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq Oct 01
Mostra tutti gli aggiornamenti
Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.24 loss in 3Q 2023) Oct 29
Ekso Bionics Holdings, Inc. to Report Q3, 2024 Results on Oct 28, 2024 Oct 21
New major risk - Shareholder dilution Sep 01 Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million. Aug 31
Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million. Aug 30
New major risk - Financial position Aug 29
Forecast to breakeven in 2026 Jul 31
New minor risk - Profitability Jul 30
Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.31 loss in 2Q 2023) Jul 30 Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jul 30
Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 22
Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors Jun 18
Forecast to breakeven in 2026 May 01
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.33 loss in 1Q 2023) Apr 30
Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024 Apr 28
Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Apr 23
No longer forecast to breakeven Mar 07
New minor risk - Profitability Mar 05
Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024 Feb 27
Forecast to breakeven in 2026 Jan 23 Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million. Jan 18
Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million. Jan 12
Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.
Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR Jan 09
Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 Jan 05
Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal Dec 12
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.33 loss in 3Q 2022) Oct 29
Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Oct 20
Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq Oct 01
New major risk - Financial position Jul 30
Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.23 loss in 2Q 2022) Jul 29
Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023 Jul 23
Executive Chairman of the Board recently sold €61k worth of stock May 29
High number of new and inexperienced directors May 03
No longer forecast to breakeven Apr 03
Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021) Mar 30
Forecast to breakeven in 2025 Dec 31
Ekso Bionics Holdings, Inc Announces Director Changes Dec 10 Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million. Dec 06
Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.15 loss in 3Q 2021) Nov 05 Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer
Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.10 loss in 2Q 2021) Jul 30
Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 22
Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients Jun 14
Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes May 27
Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022 May 02
First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.34 loss in 1Q 2021) Apr 30
Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020) Nov 04
Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020) Jul 31
First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020) May 02
Director has left the company Mar 03
Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019) Feb 28
Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021 Feb 27
Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
New 90-day high: €10.50 Feb 10
Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director Feb 09
New 90-day high: €6.40 Jan 11
Ekso Bionics Holdings, Inc. Appoints Charles Li to its Board of Directors Jan 02
New 90-day high: €6.35 Dec 24
New 90-day high: €5.00 Nov 25
New 90-day low: €3.58 Oct 31
Third-quarter earnings released: Revenue beats expectations Oct 30
Third quarter earnings released Oct 30
Ekso Bionics Holdings, Inc. Announces EGM Builders as First Customer to Adopt Evo Technology Oct 30
New 90-day low: €3.60 Oct 02
Ekso Bionics Holdings, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 24
Ekso Bionics Holdings, Inc.(NasdaqCM:EKSO) dropped from Russell Microcap Growth Index Jul 05
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $21.1M ) di 23E2 superano le sue passività a breve termine ( $7.5M ).
Passività a lungo termine: Le attività a breve termine di 23E2 ( $21.1M ) superano le sue passività a lungo termine ( $6.8M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: 23E2 ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di 23E2 si è ridotto da 51.5% a 36% negli ultimi 5 anni.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: 23E2 ha meno di un anno di cash runway in base al suo attuale free cash flow .
Previsione Cash Runway: 23E2 ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a crescere ai tassi storici del 9.1 % ogni anno.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}